SVJTY yields 9.13% · JNJ yields 2.13%● Live data
📍 SVJTY pulled ahead of the other in Year 1
Combined, SVJTY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SVJTY + JNJ for your $10,000?
Public Joint Stock Company Severstal, together with its subsidiaries, operates as an integrated steel and steel-related mining company in Russia, Europe, CIS, the Middle East, North America, Africa, Central and South America, China, and Asia. It operates through two segments, Severstal Resources and Severstal Russian Steel. The company produces iron ore pellets, iron ore concentrates, crushed stones, and ferrite strontium powder; and coking and steam coal, and hard coking coal concentrates; blast furnace unfluxed and fluxed pellets, as well as iron ore and steel. It also provides flat and long-rolled products, hot and cold-rolled flat products, galvanized and color coated products, and long-steel applications for use in automotive and construction industry; pipes for use in oil and gas pipeline projects; and cold-drawn steel products, steel shapes, railway fasteners, low carbon and high carbon wires, nails, steel fiber products, steel wire ropes, wire strands, steel meshes and fasteners, and carbonyl iron powders. In addition, the company engages in repair and construction, air transport, a ferrous scrap metal recycling, steel machining, and shipping and handling operations. It serves construction and service processing, oil and gas, energy, machinery, automotive, and other industries. The company was formerly known as Open Joint-Stock Company Severstal and changed its name to Public Joint Stock Company Severstal in December 2014. Public Joint Stock Company Severstal was founded in 1955 and is headquartered in Moscow, Russia.
Full SVJTY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.